Is There a Relationship Between Patient-Reported Satisfaction and Persistence on Overactive Bladder Syndrome Pharmacotherapy?

被引:2
|
作者
Tran, Alexis M. [1 ]
Reis, Renata [2 ]
Iyer, Shilpa [2 ]
Botros, Carolyn [2 ]
Goldberg, Roger P. [2 ]
Sand, Peter K. [2 ]
Botros, Sylvia M. [2 ]
机构
[1] Albany Med Coll, Div Female Pelv Med & Reconstruct Surg, Dept Obstet & Gynecol, Albany, NY 12208 USA
[2] Univ Chicago, Pritzker Sch Med, Div Female Pelv Med & Reconstruct Surg, Dept Obstet & Gynecol,NorthShore Univ Hlth Syst, Chicago, IL 60637 USA
来源
FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY | 2018年 / 24卷 / 03期
关键词
overactive bladder; persistence; pharmacotherapy; patient satisfaction;
D O I
10.1097/SPV.0000000000000475
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: This study aimed to determine the relationship between patient satisfaction with overactive bladder syndrome (OAB) pharmacotherapy and persistence rates. We compared persistence rates between satisfied and dissatisfied patients at designated study intervals. Methods: This was a retrospective cohort study of new patients who initiated OAB medication. Patients were classified as either satisfied or dissatisfied on the basis of a single-item treatment satisfaction question. Persistence was defined as continuous days on therapy. The measured rate of persistence was determined as the ratio of patients who persisted on medication at 4, 12, and 24 weeks. Data collection included demographic and prescription information; urinary symptom parameters, symptom and quality-of-life scales, and patient-reported outcomes. Two-sample t test or Wilcoxon rank sum test was used to compare continuous outcomes between both groups (satisfied vs not satisfied). chi(2) Test or Fisher exact test was used to compare categorical outcomes between groups. Results: We analyzed the first 116 charts that met our inclusion criteria. Satisfied and dissatisfied patients did not differ in demographic variables. Satisfied patients had a median of 461 vs 254 persistent days (P = 0.0001). Satisfied patients (12.5% vs 40%) were less likely to discontinue medication (P = 0.0068). The discontinuation-free distribution was significantly different between satisfied and dissatisfied cohorts, favoring those who reported satisfaction with OAB medication at all time points (P < 0.0001). Patients who totally discontinued pharmacotherapy were 7 times more likely to be dissatisfied (odds ratio, 7.0; P = 0.002). Conclusions: Our study helps clarify the relationship between persistence on OAB medication and treatment satisfaction. We found that persistence could serve as a surrogate marker for patient satisfaction because those who reported being satisfied were more likely to persist on therapy at all study intervals.
引用
收藏
页码:237 / 240
页数:4
相关论文
共 50 条
  • [1] Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome
    Kim, Tae Heon
    Choo, Myung-Soo
    Kim, Young-Joo
    Koh, Hyein
    Lee, Kyu-Sung
    QUALITY OF LIFE RESEARCH, 2016, 25 (08) : 2021 - 2029
  • [2] Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome
    Tae Heon Kim
    Myung-Soo Choo
    Young-Joo Kim
    Hyein Koh
    Kyu-Sung Lee
    Quality of Life Research, 2016, 25 : 2021 - 2029
  • [3] RELATIONSHIP BETWEEN PSYCHOSOCIAL FACTORS AND PATIENT-REPORTED BLADDER SYMPTOMS AND SATISFACTION
    Moghalu, Odinachi
    Stoffel, John
    Lenherr, Sara
    Elliott, Sean
    Welk, Blayne
    Herrick, Jennifer
    Presson, Angela
    Myers, Jeremy
    NEUROUROLOGY AND URODYNAMICS, 2021, 40 : S123 - S124
  • [4] Patient-reported outcomes in overactive bladder - Introduction
    Brubaker, Linda
    Chapple, Christopher
    UROLOGY, 2006, 68 (2A) : 1 - 2
  • [5] Patient-reported reasons for discontinuing overactive bladder medication
    Benner, Joshua S.
    Nichol, Michael B.
    Rovner, Eric S.
    Jumadilova, Zhanna
    Alvir, Jose
    Hussein, Mohamed
    Fanning, Kristina
    Trocio, Jeffrey N.
    Brubaker, Linda
    BJU INTERNATIONAL, 2010, 105 (09) : 1276 - 1282
  • [6] A RETROSPECTIVE COMPARISON OF PERSISTENCE ON PHARMACOTHERAPY FOR OVERACTIVE BLADDER SYNDROME AMONGST SPECIALTIES
    Tran, Alexis
    Sand, Peter
    Tomezsko, Janet
    Zhou, Ying
    Seitz, Miriam
    Gafni-Kane, Adam
    Botros, Sylvia
    NEUROUROLOGY AND URODYNAMICS, 2015, 34 : S92 - S92
  • [7] Pharmacotherapy of overactive bladder syndrome
    Robinson, Dudley
    Cardozo, Linda
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2008, 1 (01) : 163 - 175
  • [8] Persistence with overactive bladder pharmacotherapy in a medicaid population
    Shaya, FT
    Blume, S
    Gu, A
    Zyczynski, T
    Jumadilova, Z
    AMERICAN JOURNAL OF MANAGED CARE, 2005, 11 (04): : S121 - S129
  • [9] Patient-reported reasons for discontinuing overactive bladder (OAB) medications
    Brubaker, L.
    Nichol, M.
    Fanning, K.
    Becker, R.
    Jumadilova, Z.
    Benner, J.
    NEUROUROLOGY AND URODYNAMICS, 2006, 25 (06) : 614 - 614
  • [10] Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
    Kim, Kyu Shik
    Moon, Hong Sang
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2016, 20 (04) : 349 - 355